XPOVIO was developed by Karyopharm Therapeutics, a Newton, Massachusetts company established by Israel’s Dr. Sharon Shacham.
“We believe that our activity at Karyopharm constitutes an important milestone in the war on cancer,” she said.
The FDA first approved the drug for sale in July after 10 years of development. Karyopharm wrote in a press release that within six days of the FDA’s approval, cancer patients in the USA began receiving XPOVIO.
